Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.
Int J Mol Sci. 2023 Jul 14;24(14):11445. doi: 10.3390/ijms241411445.
Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due to the activation of the mucosa-associated immune response. However, there is no clear evidence of a vector design that could be considered preferable. To find the optimal structure of an influenza vector with a modified NS genomic segment, we constructed four vector expressing identical transgene sequences inherited from the F protein of the respiratory syncytial virus (RSV). Two vectors were designed aiming at transgene accumulation in the cytosol. Another two were supplemented with an IgGκ signal peptide prior to the transgene for its extracellular delivery. Surprisingly, adding the IgGκ substantially enhanced the T-cell immune response to the CD8 epitope of the transgene. Moreover, this strategy allowed us to obtain a better protection of mice from the RSV challenge after a single intranasal immunization. Protection was achieved without antibodies, mediated by a balanced T-cell immune response including the formation of the RSV specific effector CD8+ IFNγ+/IL10+-producing cells and the accumulation of Treg cells preventing immunopathology in the lungs of infected mice. In addition to the presented method for optimizing the influenza vector, our results highlight the possibility of achieving protection against RSV through a respiratory-associated T-cell immune response alone.
鼻腔内接种流感载体是一种很有前途的方法,可以开发针对呼吸道病原体的疫苗,因为它可以激活黏膜相关的免疫反应。然而,目前还没有明确的证据表明哪种载体设计可以被认为是更优的。为了找到具有改良 NS 基因组片段的流感载体的最佳结构,我们构建了四个表达相同的转基因序列的载体,这些序列来自呼吸道合胞病毒(RSV)的 F 蛋白。两个载体的设计目的是使转基因在细胞质中积累。另外两个载体在转基因前添加了 IgGκ 信号肽,以便其在细胞外递呈。令人惊讶的是,添加 IgGκ 大大增强了 T 细胞对转基因 CD8 表位的免疫反应。此外,这种策略使我们能够在单次鼻腔免疫接种后更好地保护小鼠免受 RSV 攻击。这种保护是通过一种平衡的 T 细胞免疫反应来实现的,包括形成 RSV 特异性效应 CD8+ IFNγ+/IL10+-产生细胞和积累 Treg 细胞,防止感染小鼠肺部的免疫病理学。除了提出的优化流感载体的方法外,我们的结果还强调了通过呼吸道相关的 T 细胞免疫反应单独实现 RSV 保护的可能性。